Nothing Special   »   [go: up one dir, main page]

ATE120497T1 - Verfahren zur voraussage der wirksamkeit einer antineoplastichen behandlung bei einzelnen patienten. - Google Patents

Verfahren zur voraussage der wirksamkeit einer antineoplastichen behandlung bei einzelnen patienten.

Info

Publication number
ATE120497T1
ATE120497T1 AT89304494T AT89304494T ATE120497T1 AT E120497 T1 ATE120497 T1 AT E120497T1 AT 89304494 T AT89304494 T AT 89304494T AT 89304494 T AT89304494 T AT 89304494T AT E120497 T1 ATE120497 T1 AT E120497T1
Authority
AT
Austria
Prior art keywords
effectiveness
individual patients
expression
predicting
antineoplastic treatment
Prior art date
Application number
AT89304494T
Other languages
English (en)
Inventor
Alan M Gewirtz
Bruno Calabretta
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Application granted granted Critical
Publication of ATE120497T1 publication Critical patent/ATE120497T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/811Test for named disease, body condition or organ function
    • Y10S436/813Cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT89304494T 1988-05-09 1989-05-04 Verfahren zur voraussage der wirksamkeit einer antineoplastichen behandlung bei einzelnen patienten. ATE120497T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19144988A 1988-05-09 1988-05-09

Publications (1)

Publication Number Publication Date
ATE120497T1 true ATE120497T1 (de) 1995-04-15

Family

ID=22705545

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89304494T ATE120497T1 (de) 1988-05-09 1989-05-04 Verfahren zur voraussage der wirksamkeit einer antineoplastichen behandlung bei einzelnen patienten.

Country Status (5)

Country Link
US (1) US5427916A (de)
EP (1) EP0341904B1 (de)
JP (1) JPH0636759B2 (de)
AT (1) ATE120497T1 (de)
DE (1) DE68921918T2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005286A1 (en) * 1990-09-24 1992-04-02 Roger Brent Screening assays
ES2092056T3 (es) * 1991-09-23 1996-11-16 Pfizer Procedimiento para detectar arnm y adn especificos en celulas.
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
EP0646174A1 (de) * 1992-06-16 1995-04-05 The Whittier Institute For Diabetes And Endocrinology Rekombinante herstellung von saporin-enthaltenden proteinen
ES2091018T3 (es) * 1992-06-18 1996-10-16 Whittier Inst Diabetes & Endoc Procedimiento para la deteccion de enfermedades neoplasicas.
GB9220777D0 (en) * 1992-10-02 1992-11-18 Univ Leicester Oligonucleotide probes
US5763198A (en) * 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
JP2000510330A (ja) 1996-04-05 2000-08-15 トーマス・ジェファーソン・ユニバーシティ 癌の診断および予後のための方法
US5955269A (en) * 1996-06-20 1999-09-21 Rutgers, The State University Of New Jersey Methods of screening foods for nutraceuticals
AU7987800A (en) * 1999-09-29 2001-04-30 Lifespan Biosciences, Inc. Anti-aging nucleic acid and protein targets
WO2002039121A2 (en) * 2000-11-03 2002-05-16 Board Of Regents, The University Of Texas System Methods for detecting the efficacy of anticancer treatments
EP1713938A2 (de) 2004-02-09 2006-10-25 Thomas Jefferson University Diagnose und behandlung von krebserkrankungen mit oder nahe mit krebs in zusammenhang stehenden chromosomalen merkmalen lokalisierter microrna
US7012200B2 (en) * 2004-02-13 2006-03-14 Sonion Roskilde A/S Integrated volume control and switch assembly
US20060019972A1 (en) * 2004-04-27 2006-01-26 California Institute Of Technology Methods of treating cancer by inhibiting histone gene expression
US20080261207A1 (en) * 2004-05-25 2008-10-23 Masato Mitsuhashi Method of Measuring Cancer Susceptibility
EP1802776B1 (de) * 2004-10-20 2013-01-02 Hitachi Chemical Company, Ltd. Verfahren zur anpassung der arzneimittelverabreichung durch quantifizierung von mrna
WO2006086681A2 (en) * 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting smooth muscle cell migration and proliferation
JP4945554B2 (ja) * 2005-04-28 2012-06-06 ヒタチ ケミカル リサーチ センター インコーポレイテッド 食物サプリメントに対する個体変動評価のモデルとしての全血におけるexvivo遺伝子発現
JP2009501024A (ja) * 2005-07-12 2009-01-15 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 癌の診断及び治療における遺伝的及びエピジェネティックな変化
AU2006291165B2 (en) 2005-09-12 2013-03-14 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
ES2526787T3 (es) 2006-01-05 2015-01-15 The Ohio State University Research Foundation Métodos basados en microARN para el diagnóstico de cánceres de colon, páncreas y estómago
EP1968622B1 (de) 2006-01-05 2014-08-27 The Ohio State University Research Foundation Mikro-rna-expressions-anomalien in pankreas- und azinus-tumoren
US7943318B2 (en) 2006-01-05 2011-05-17 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
EP2522749A1 (de) 2006-03-02 2012-11-14 The Ohio State University Mikro-RNA-Expressionsprofil im Zusammenhang mit Bauchspeicheldrüsenkrebs
EP2371971B1 (de) 2006-03-20 2013-11-27 The Ohio State University Research Foundation Mikro-RNA-Fingerabdrücke während humaner Megakaryozytopoiese
US20090298071A1 (en) * 2006-05-08 2009-12-03 Masato Mitsuhashi Method for testing drug sensitivity in solid tumors by quantifying mrna expression in thinly-sliced tumor tissue
WO2007134142A2 (en) * 2006-05-11 2007-11-22 University College Dublin Methods and compositions for identifying and using p21-regulated proteins
ES2434090T3 (es) 2006-07-13 2013-12-13 The Ohio State University Research Foundation MIR-29a para el diagnóstico de adenocarcinoma de colon con mal pronóstico de supervivencia
US8841436B2 (en) * 2007-03-15 2014-09-23 University Hospitals Cleveland Medical Center Screening, diagnosing, treating and prognosis of pathophysiologic status by RNA regulation
CN103602724B (zh) 2007-06-08 2016-03-16 由卫生与公众服务部代表的美利坚合众国政府 确定肝细胞癌亚型和检测肝癌干细胞的方法
WO2009012263A2 (en) * 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
ES2496172T3 (es) 2007-07-31 2014-09-18 The Ohio State University Research Foundation Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B
EP2650383A1 (de) 2007-08-03 2013-10-16 The Ohio State University Research Foundation Ultrakonservierte Bereiche zur Codierung von ncRNA
CA2926831A1 (en) 2007-08-22 2009-02-26 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
AU2008296022B2 (en) 2007-09-06 2014-01-23 The Ohio State University Research Foundation MicroRNA signatures in human ovarian cancer
CN103937876B (zh) 2007-10-11 2016-08-17 俄亥俄州立大学研究基金会 用于诊断和治疗食管腺癌的方法和组合物
JP2011502535A (ja) * 2007-11-14 2011-01-27 日立化成工業株式会社 末梢血白血球における、Fc受容体を介した腫瘍壊死因子スーパーファミリーmRNA発現
US20090215064A1 (en) * 2008-02-27 2009-08-27 Hitachi Chemical Co., Ltd. Quantitative assessment of individual cancer susceptibility by measuring dna damage-induced mrna in whole blood
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
JP2012515532A (ja) 2009-01-20 2012-07-12 ラモット アット テル アビブ ユニバーシティ, リミテッド Mir−21プロモーター駆動性標的がん治療
WO2010105096A2 (en) 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
WO2010149666A1 (en) 2009-06-22 2010-12-29 Medexis S.A. Methods for treating neoplasia
JP2013502906A (ja) 2009-08-31 2013-01-31 アルケド バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 染色体再編成を伴う腫瘍の診断、予後及び治療のためのマイクロrnaに基づいた方法及び組成物
WO2011029639A2 (en) 2009-09-08 2011-03-17 Medexis S.A. Compounds and methods for treating neoplasia
WO2011109637A1 (en) 2010-03-03 2011-09-09 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers
US20130303500A1 (en) 2010-07-30 2013-11-14 Medexis S.A. Compounds and methods for treating neoplasia
WO2012025633A1 (en) 2010-08-27 2012-03-01 University Of Zurich A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
EP2546358A1 (de) 2011-07-15 2013-01-16 Laboratorios Del. Dr. Esteve, S.A. Verfahren und Reagenzien zur effizienten Steuerung des HIV-Fortschritts
AU2012323924A1 (en) 2011-10-14 2014-05-29 The Ohio State University Methods and materials related to ovarian cancer
WO2014145254A2 (en) 2013-03-15 2014-09-18 Sutter West Bay Hospitals Falz for use as a target for therapies to treat cancer
WO2015006543A1 (en) 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis in kidney cancer
JP6624704B2 (ja) 2015-08-31 2019-12-25 日立化成株式会社 尿路上皮疾患の評価のための分子法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI76119C (fi) * 1986-02-27 1988-09-09 Orion Yhtymae Oy Kvantitativ bestaemning av nukleinsyramolekyler och reagensfoerpackning som anvaends vid foerfarandet.
NO881560L (no) * 1987-05-05 1988-11-07 Hope City Fremgangsmaate for detektering av begynnende resistens motterapeutiske midler i kreftpasienter.

Also Published As

Publication number Publication date
JPH0213400A (ja) 1990-01-17
EP0341904A3 (de) 1991-11-27
US5427916A (en) 1995-06-27
EP0341904A2 (de) 1989-11-15
DE68921918D1 (de) 1995-05-04
JPH0636759B2 (ja) 1994-05-18
DE68921918T2 (de) 1995-09-07
EP0341904B1 (de) 1995-03-29

Similar Documents

Publication Publication Date Title
ATE120497T1 (de) Verfahren zur voraussage der wirksamkeit einer antineoplastichen behandlung bei einzelnen patienten.
ATE360989T1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
DE3782917D1 (de) Verfahren zum herabsetzen des gehalts an rueckstaendigen aldehyden in implantierbaren bioprosthetischen geweben.
DE3869490D1 (de) Verfahren zur elektrochemischen behandlung von stoffen.
IE46078L (en) Apparatus for treating living tissues and/or cells by¹electromagnetically inducing voltage and current pulses¹within the tissue and/or cells.
PT87086A (pt) Active specific immune suppression
DE3766534D1 (de) Verfahren und system zum anreichern von wasser mit sauerstoff.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE3880118D1 (de) Verwendung eines mittels in form von mikrokapseln zur schabenbekaempfung.
DE3675632D1 (de) Verfahren zur einbringung von sauerstoff in wasser und vorrichtung zur durchfuehrung des verfahrens.
DE3874019D1 (de) Verfahren zur konservierung von transplantierbaren, in vitro kultivierten epithelgeweben.
DE68905117D1 (de) Verfahren zur stabilisierung von blutgewinnungsfaktoren.
ATA521376A (de) Verfahren und vorrichtung zum kultivieren von tierischen und humanen gewebezellen
DE3869230D1 (de) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin.
NO882854D0 (no) Korreksjon med dobbeltraadet rna av avvikende metabolske spor forbundet med ukontrollerte vekstsykluser for tumorceller og virus.
AT383491B (de) Vorrichtung zum verabreichen von voll- oder sitz- baedern, insbesondere unter verwendung von peloid
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
NO884061D0 (no) Fremgangsmaate for regulering av surhetsgraden i et elektrolytisk bad.
AT380863B (de) Verfahren und vorrichtung zur biologischen anaeroben denitrifikation von aquariumwasser
DE3862788D1 (de) Fluessige oxydationsmodifizierte ethylenische statistische copolymere, verfahren zur herstellung und deren verwendung.
FR2492262B1 (fr) Procede et dispositif de commande d'un appareil ou instrument notamment un stimulateur cardiaque implantable
DE3884777D1 (de) Verfahren zur Herstellung von Pregneno-Oxazolinen.
DE3889232D1 (de) Verfahren zum quantitativen Nachweis von Sauerstoff.
FI113153B (fi) Solukasvunsäätelijä
SE9102014D0 (sv) Foerfarande i samband med mammalieceller